ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Mauna Kea Technologies's annualized return on capital (ROC %) for the quarter that ended in Dec. 2023 was 22.14%.
As of today (2024-05-17), Mauna Kea Technologies's WACC % is 4.69%. Mauna Kea Technologies's ROC % is 10.92% (calculated using TTM income statement data).
Mauna Kea Technologies generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note:
The Operating Income data used here is two times the semi-annual (Dec. 2023) data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.
There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.
Why is ROC % important?
Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Mauna Kea Technologies's WACC % is 4.69%. Mauna Kea Technologies's ROC % is 10.92% (calculated using TTM income statement data).
Mauna Kea Technologies generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.
Be Aware
Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Mauna Kea Technologies ROC % Related Terms
Thank you for viewing the detailed overview of Mauna Kea Technologies's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Mauna Kea Technologies (Mauna Kea Technologies) Business Description
Mauna Kea Technologies SA is a medical device corporation. It is engaged in designing, developing, and marketing an imaging platform used to view tissues at a cellular level, in real-time, during standard procedures. The firm operates in the business segment of Endomicroscopy. The group's technological platform is Cellvizio which helps physicians to detect early-stage pathologies more accurately and make therapeutic decisions. It generates revenue from the sales of Cellvizio products and accessories used for medical diagnostics, research, and related services. The company sells its products in France and internationally, of which the majority of the revenue is derived from America.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MKEAF has been successfully added to your 